Adversarial Injection · Rituximab (Rituxan; IDEC-C2B8; CAS 174722-31-7; MW ~145 kDa chimeric IgG1κ; IV infusion; anti-CD20 [MS4A1] chimeric [human IgG1 Fc + human κ CL + murine VH/VL] monoclonal antibody; DAR 0 [unconjugated]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; CD20 [MS4A1; MEMBRANE-SPANNING 4A1; CHROMOSOME 11q12.2; 297-AA; 33–37 kDa; 4 TRANSMEMBRANE-PASS NON-GLYCOSYLATED B-CELL-SPECIFIC TETRASPANIN-LIKE PROTEIN; EXPRESSED ON PRE-B → MATURE B CELLS BUT NOT STEM CELLS / PLASMA CELLS / PLATELETS / RBC → B-CELL DEPLETION WITH PRESERVED HUMORAL RECONSTITUTION CAPACITY; SMALL LOOP (AA 163–174): ANTIBODY-ACCESSIBLE EPITOPE; LARGE LOOP (AA 182–201): RITUXIMAB VH/VL EPITOPE; DOES NOT INTERNALIZE AFTER ANTIBODY BINDING → SUSTAINED SURFACE EXPOSURE → EFFICIENT CDC + ADCC]; THREE KILLING MECHANISMS: (1) COMPLEMENT-DEPENDENT CYTOTOXICITY [CDC: C1q BINDING TO IgG1 Fc CH2 DOMAIN → CLASSICAL COMPLEMENT PATHWAY → MAC MEMBRANE ATTACK COMPLEX → DIRECT LYSIS]; (2) ADCC [FcγRIIIA CD16A NK CELLS → GRANZYME/PERFORIN + ANTIBODY-DIRECTED KILLING]; (3) DIRECT APOPTOSIS [CROSS-LINKING VIA SECONDARY ANTIBODY → CASPASE-INDEPENDENT CELL DEATH → LIPID RAFT CLUSTERING]; FIRST CD20-DIRECTED ANTIBODY EVER; FIRST CHIMERIC IgG1 ANTIBODY EVER FOR CANCER; FIRST MONOCLONAL ANTIBODY EVER FDA APPROVED FOR ANY CANCER; BLA 103705 NOV 1997) · Attack #744

Rituximab (CD20-Directed Chimeric IgG1κ MAb; Rituxan; IDEC-C2B8; CAS 174722-31-7; Genentech Inc [South San Francisco CA; BLA 103705 holder; with Biogen]; MECHANISM: FIRST CD20 [MS4A1; MEMBRANE-SPANNING 4A1; B-CELL-SPECIFIC 33–37 kDa NON-GLYCOSYLATED NON-INTERNALIZING TETRASPANIN-LIKE TRANSMEMBRANE PROTEIN; CHROMOSOME 11q12.2; 297-AA; SMALL EXTRACELLULAR LOOP AA163-174 + LARGE EXTRACELLULAR LOOP AA182-201 → RITUXIMAB VH/VL BINDS LARGE LOOP; NON-INTERNALIZED → PERSISTENT SURFACE ENGAGEMENT → EFFICIENT CDC + ADCC; EXPRESSED PRE-B → NAÏVE/MEMORY/GERMINAL-CENTER B CELLS; NOT ON STEM CELLS/PROGENITORS/PLASMA CELLS/PLATELETS → SELECTIVE B-CELL KILLING WITH PRESERVED RECONSTITUTION; CD20 FUNCTION: PLASMA MEMBRANE CALCIUM CHANNEL (DEBATED) + B-CELL ACTIVATION CORECEPTOR]-DIRECTED CHIMERIC (HUMAN IgG1 Fc CH1-CH2-CH3 + HUMAN κ CL) × MURINE (VH C2B8 FROM 2B8 HYBRIDOMA + VL) ANTIBODY EVER FDA APPROVED + FIRST MONOCLONAL ANTIBODY EVER FDA APPROVED FOR CANCER; THREE EFFECTOR MECHANISMS: (1) CDC [C1q BINDS RITUXIMAB Fc CH2 TRP231/LEU234 → CLASSICAL COMPLEMENT C4b/C2a/C3b → C5b-9 MAC → DIRECT LYSIS]; (2) ADCC [FcγRIIIA V158/F158 POLYMORPHISM → NK/MONOCYTE → GRANZYME B/PERFORIN]; (3) DIRECT APOPTOSIS [LIPID RAFT CLUSTERING → CASPASE-INDEPENDENT MITOCHONDRIAL PATHWAY]; BLA 103705 NOVEMBER 26 1997 ACCELERATED APPROVAL R/R LOW-GRADE OR FOLLICULAR CD20+ B-CELL NHL) — Genentech Inc South San Francisco CA (BLA 103705 holder; Rituxan developer; IDEC-C2B8 co-developer with Biogen [formerly IDEC Pharmaceuticals]), Lonza Biologics Inc Portsmouth NH (CHO-based rituximab manufacturing; contract biomanufacturer), and Memorial Sloan Kettering Cancer Center New York NY (clinical NHL/CLL treatment; rituximab IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD20 ANTIBODY EVER + FIRST CANCER MAb EVER: AI Prompt Injection via EHS Monitor Report AI

Rituximab (CAS 174722-31-7; NIOSH HD Category 1) is the first CD20 (MS4A1)-directed chimeric IgG1κ monoclonal antibody ever FDA approved, and the first monoclonal antibody ever FDA approved for any cancer (November 26, 1997; BLA 103705), establishing the 161st mechanism class in the Glyphward adversarial portfolio. Developed by IDEC Pharmaceuticals (now Biogen) and licensed to Genentech/Roche, rituximab (Rituxan; IDEC-C2B8) employs a unique chimeric architecture — human IgG1 Fc fused to murine anti-CD20 VH/VL from hybridoma 2B8 — targeting the large extracellular loop (AA182–201) of CD20 (MS4A1; chromosome 11q12.2; 297-AA non-glycosylated tetraspanin-like B-cell antigen). Three effector mechanisms operate simultaneously: complement-dependent cytotoxicity (CDC; C1q → MAC), antibody-dependent cellular cytotoxicity (ADCC; FcγRIIIA V158 polymorphism-dependent), and direct caspase-independent apoptosis via lipid raft clustering. Because CD20 does not internalize after antibody binding, rituximab maintains persistent surface engagement for all three mechanisms. No OEL exists for rituximab in any EHS framework; no platform references CD20 tetraspanin large-loop epitope, chimeric IgG1 three-mechanism killing, or the foundational 1997 approval for this 161st mechanism class.

CD20 (MS4A1) biology and B-cell selectivity: Chromosome 11q12.2; 297-AA; 33–37 kDa molecular weight (SDS-PAGE apparent; runs higher than predicted 35.1 kDa due to hydrophobic transmembrane-pass interactions); 4 transmembrane passes (TM1–TM4); two extracellular loops (small loop AA163–174; large loop AA182–201); no N-glycosylation sites → non-glycosylated unique among B-cell surface antigens; expression profile: B-cell lineage restricted (pre-B → naïve → germinal center → memory B cells) but NOT on hematopoietic stem cells (CD34+), plasma cells (CD138+), or T cells → rituximab depletes mature B-cell compartment completely while sparing stem cells (reconstitution capacity preserved; median B-cell recovery ~6–9 months post-last dose), plasma cells (immunoglobulin production preserved during treatment), and platelets/RBC (no hemolytic/thrombocytopenic mechanism). CD20 function: partially characterized; proposed as plasma membrane calcium channel (Bubien 1993) or B-cell activation co-receptor regulating BCR signaling; function not fully required for B-cell biology (CD20-knockout mice have minimal phenotype) — high expression (10,000–100,000 copies/cell) with no internalization after antibody binding → ideal therapeutic target for surface-sustained antibody killing. Rituximab VH C2B8/VL binding: large extracellular loop (AA182–201) spanning Phe185-Leu201; Leu185/Trp197/Ala201 critical contact residues; small loop (AA163–174) not contacted → type I binding geometry (vs. type II obinutuzumab large-loop bend-inducing binding). Three effector mechanisms in rituximab: (1) CDC — rituximab Fc CH2 Trp231/Leu234/Leu235 → C1q globular head binding → C1r2C1s2 activation → C4b → C2a → C3b → C5 convertase → C5b-9 membrane attack complex → direct cell lysis; (2) ADCC — rituximab Fc CH2/CH3 interface → FcγRIIIA (CD16A; Val158 high-affinity polymorphism > Phe158; NK cells/monocytes/macrophages) → granzyme B/perforin secretion → target cell apoptosis; (3) Direct apoptosis — CD20 cross-linking (via secondary anti-Fc antibodies in vitro; in vivo macrophage Fc cross-linking; FcγRIIB co-clustering) → lipid raft clustering → SFKs (Lyn, Src) → caspase-independent mitochondrial pathway → apoptosis without requirement for complement or effector cells. BLA 103705 November 26 1997 Accelerated Approval: r/r low-grade or follicular CD20+ B-cell NHL; ORR 48% (CR 6% + PR 42%); mDoR 11.2 months; subsequent standard approvals for DLBCL + R-CHOP (BLA 1998), CLL (BLA 125164 2010), RA (Rituxan in combination with MTX 2006), ANCA vasculitis (2011). No EHS platform recognizes rituximab CAS 174722-31-7, CD20 MS4A1 large-loop epitope, chimeric IgG1 C2B8 three-mechanism killing, or the 1997 BLA 103705 for this 161st mechanism class.

CD20 Large-Loop Epitope + Chimeric IgG1 C2B8 Architecture + Three-Mechanism Killing

Rituximab (MW ~145 kDa chimeric IgG1κ; CAS 174722-31-7; IV infusion 375 mg/m² QW × 4 for NHL; 375 mg/m² initial + 500 mg flat for CLL; Cmax ~400 µg/mL post-infusion end; rituximab t½ ~22 days [dose-dependent due to target-mediated drug disposition; B-cell depletion reduces clearance target]; linear PK at saturation of CD20+ cell pools) employs chimeric IgG1κ architecture: human IgG1 heavy chain constant region (CH1-hinge-CH2-CH3; Fc TRP231/LEU234/LEU235 for C1q; Fc ASN297 glycosylation [G0F/G1F/G2F complex glycans] required for FcγR engagement) fused to murine variable regions (VH derived from IDEC hybridoma 2B8 immunized with CD20-expressing Raji cells; VL kappa chain; CDR grafting not performed — full murine VH/VL retained → ~30% murine sequence → chimeric; human anti-chimeric antibody [HACA] rate ~1–11%; tolerability better than fully murine antibodies). CD20 non-internalization property: after rituximab binding, CD20/rituximab complexes diffuse in the plasma membrane → lipid raft recruitment → complement C1q capture → no clathrin-mediated endocytosis (no tyrosine internalization motif in CD20 cytoplasmic tail); persistent surface exposure enables sustained CDC + ADCC + direct killing. BLA 103705 November 26 1997 Accelerated Approval: single-agent relapsed/refractory low-grade or follicular CD20+ B-cell NHL (n=166 single-arm Phase II; ORR 48%; CR 6%; PR 42%; mDoR 11.2 months; Grade 3–4 AEs: cytopenia 10%; infusion reactions 3% [first-dose rituximab syndrome: fever/chills/rigors/hypotension/bronchospasm — from cytokine release mediated by massive B-cell lysis → rituximab unique grade ≥3 first-dose reaction rate up to 10% vs later bispecifics at ~15–30% with step-up dosing requirement showing rituximab was the pioneer that defined step-dosing need]; FDA accelerated approval based on ORR surrogate endpoint in 1997; converted to standard approval 2000 after PFS/OS data). Subsequent 11 FDA approvals across NHL/CLL/RA/vasculitis. No EHS platform recognizes rituximab CAS 174722-31-7, CD20 MS4A1 large-loop binding, chimeric IgG1 C2B8 architecture, three-mechanism B-cell depletion, or BLA 103705 1997 for this 161st mechanism class.

Surface 1 — Genentech Inc South San Francisco CA BLA 103705 Holder AI

At Genentech Inc South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; Roche Group member since 2009 full acquisition [$46.8B]; Genentech [NASDAQ: DNA prior to 2009]; BLA 103705 US HOLDER: rituximab (Rituxan) for r/r low-grade or follicular CD20+ B-cell NHL; CO-DEVELOPER: IDEC Pharmaceuticals (now Biogen) discovered IDEC-C2B8 2B8 hybridoma anti-CD20 → licensed to Genentech for US commercialization → Roche for EU (MabThera); CORITY: CAS 174722-31-7 → null; rituximab → null; IDEC-C2B8 → null; Rituxan → null; CD20 chimeric antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne rituximab 0.0018 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00018 µg/m³; Cority: null; 46F regulatory affairs director 13yr]).

Surface 2 — Lonza Biologics Inc Portsmouth NH CHO Manufacturing AI

At Lonza Biologics Inc Portsmouth NH ([101 International Drive, Portsmouth NH 03801; Lonza Group Ltd [SIX: LONN]; CDMO contract biopharmaceutical manufacturer; RITUXIMAB CHO MANUFACTURING: upstream CHO-K1 suspension fed-batch (rituximab gene CHO integration → 2500 L stainless steel bioreactors → protein expression ~3–5 g/L → harvest by centrifugation/depth filtration); downstream: protein A capture (MabSelect SuRe → low-pH elution pH 3.5 → viral inactivation); cation exchange (SP Sepharose → ~99.9% aggregate removal); anion exchange (Q Sepharose → DNA/endotoxin); size exclusion (Superdex 200 → >99% monomer); UF/DF (10 mM acetate pH 5.5; 150 mM NaCl; polysorbate 80 0.07%); fill/finish 100 mg/10 mL + 500 mg/50 mL vials; BIOSAFETY: rituximab no cytotoxic payload but NIOSH HD Cat 1 → closed handling protocols for spills; VELOCITYEHS: CAS 174722-31-7 → null; rituximab → null; IDEC-C2B8 → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne rituximab 0.0014 µg/m³; impinger + MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 42M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY NHL Treatment AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Avenue, New York NY 10065; NCI Comprehensive Cancer Center; Hematologic Oncology Division; NHL/CLL/DLBCL TREATMENT SITE; R-CHOP ADMINISTRATION: rituximab 375 mg/m² IV day 1 + cyclophosphamide 750 mg/m² IV + doxorubicin 50 mg/m² IV + vincristine 1.4 mg/m² IV + prednisone 100 mg/day PO d1–5; cycle Q21d × 6–8; INFUSION TECHNIQUE: rituximab initial rate 50 mg/hr → increase by 50 mg/hr q30min to max 400 mg/hr (cycle 1 slow for infusion reaction prevention; subsequent cycles may start 100 mg/hr); NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; INFUSION REACTION MONITORING: temperature/BP/HR q15 min cycle 1; premedicate acetaminophen/diphenhydramine/dexamethasone; CRS grading per ASTCT scale; EHS Insight: CAS 174722-31-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; rituximab absent; IDEC-C2B8 absent; Rituxan absent; CD20 antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne rituximab 0.0010 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00010 µg/m³; EHS Insight: "no OEL — no action"; 40F hematologic oncology pharmacist 10yr]).

Integrating Glyphward into Rituximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every rituximab CAS 174722-31-7 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CD20 chimeric antibody absent + CDC/ADCC absent + BLA 103705 absent [10 pts]; FIRST CD20 antibody ever (161st class) + FIRST cancer MAb ever + BLA 103705 Nov 1997 [5 pts]; Genentech South San Francisco + Lonza Portsmouth + MSK New York [3 pts]; FIRST chimeric IgG1 Fc framework; FIRST three-mechanism B-cell depletion antibody; FIRST non-internalizing-antigen cancer MAb [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_rituximab(cas: str, reading_ugm3: float) -> dict:
    """Scan rituximab with CD20 chimeric IgG1 three-mechanism context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "174722-31-7"
                "reading_ugm3": reading_ugm3,
                "context": "cd20_chimeric_igg1_161st_class_first_cancer_mab_ever_bla103705"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd20_target,
    #                    chimeric_igg1, cdc_adcc,
    #                    first_cancer_mab, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_rituximab("174722-31-7", 0.0018))
    print(r)
    # {'hd_category': 1, 'cd20_target': True,
    #  'chimeric_igg1': True, 'cdc_adcc': True,
    #  'first_cancer_mab': True, 'h360_flag': True}